Federal contract award
75N95021F00002
EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | 75N95019D00012 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $452.9K |
| Current contract value | $452.9K |
| Potential contract value / ceiling | $452.9K |
| Start date | Sep 29, 2021 |
| Current end date | May 31, 2026 |
| Potential end date | May 31, 2026 |
| Latest award activity | May 29, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 29, 2026 | P00003 | $86.0K | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. |
| May 7, 2025 | P00002 | $-257.0K | EOI::HHS COST EFFICIENCY INITIATIVE::EOI PARTIAL TERMINATION FOR CONVENIENCE - DESCOPE |
| Aug 16, 2023 | P00001 | $0 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. |
| Sep 28, 2021 | 0 | $623.9K | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.